Generate Biomedicines (NASDAQ:GENB) Sets New 1-Year High – Still a Buy?

Generate Biomedicines Inc (NASDAQ:GENB)’s share price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $16.79 and last traded at $16.2890, with a volume of 484229 shares traded. The stock had previously closed at $15.43.

Analyst Ratings Changes

GENB has been the subject of several analyst reports. Morgan Stanley increased their price target on shares of Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, May 14th. HC Wainwright increased their price objective on Generate Biomedicines from $16.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Cantor Fitzgerald started coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They set an “overweight” rating for the company. Wall Street Zen lowered Generate Biomedicines from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, The Goldman Sachs Group assumed coverage on Generate Biomedicines in a report on Tuesday, March 24th. They set a “buy” rating and a $26.00 price target for the company. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $25.40.

Generate Biomedicines Stock Performance

The business’s fifty day moving average is $13.54.

Generate Biomedicines (NASDAQ:GENB) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.59).

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.